Sort
10,829 grants matching “car t”
Accelerate cellular immunotherapy development for treatment of life-threatening childhood disorders
$1,386,496Julie R Park · Seattle Children'S Hospital · U01 · FY2020 · TR
NSF POSE: Phase II: Open-source ecosystem for nucleic acid nanotechnology modeling
$1,384,726Petr Sulc · Arizona State University · · FY2024 · TIP
Thoracic and Gastrointestinal Malignancies Branch Clinical Core
$1,381,210Raffit Hassan · Division Of Basic Sciences - Nci · ZID · FY2021 · CA
III: Large: Collaborative Research: Moving Objects Databases for Exploration of Virtual and Real Environments
$1,379,000Naphtali D Rishe · Florida International University · · FY2012 · CSE
Targeting FGFR4, RAS, and PAX3-FOXO1 gene in Rhabdomyosarcoma
$1,378,435Javed Khan · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Programming T Cell Fates for Therapeutic Use
$1,374,247Luca Gattinoni · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Core B: GMP Cell and RNA Manufacturing
$1,373,779Bruce L. Levine · University Of Pennsylvania · P01 · FY2017 · CA
CAR-T cell treatment of CNS Autoimmunity
$1,365,252Gregory Wu · Washington University · R01 · FY2025 · AI
New Down syndrome brain organization revealed by single-cell genomics
$1,362,937Jerold Chun · Sanford Burnham Prebys Medical Discovery Institute · R56 · FY2022 · AG
CLINICAL TRANSLATION OF GUCY2C CAR-T-CELL THERAPY
$1,360,616Thomas Jefferson University · · FY2019 · Department of the Army
Synthetic metabolism to armor and enhance a new class of cell therapies
$1,356,578John James Blazeck · Georgia Institute Of Technology · DP2 · FY2022 · CA
PROTECT (Harnessing PROTEin degradation for Advanced Childhood Tumors)
$1,355,618Kimberly Stegmaier · Dana-Farber Cancer Inst · OT2 · FY2024 · CA
A Novel Class of Synthetic Receptors to Empower the Age of mRNA Therapies
$1,350,770Xiaojing J Gao · Stanford University · DP2 · FY2023 · EB
Clinical Research Correlatives Core
$1,345,055Kaska Wloka · Division Of Basic Sciences - Nci · ZIC · FY2023 · CA
CAR T cells targeting mesothelin and secreting bispecific antibodies targeting fibroblasts in pancreatic cancer
$1,342,869Marcela Valderrama Maus · Massachusetts General Hospital · UG3 · FY2024 · CA
Revolutionizing CAR T-cell Therapy: Enhancing Activity and Persistence of CAR T-cell by Developing a CAR-Enhancer Platform
$1,340,987Hamid Mahini · Koi Biotherapeutics Inc. · R44 · FY2025 · CA
Development of new antibody-based cancer therapies
$1,340,134Mitchell Ho · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
$1,338,702David Jay Miklowitz · University Of California Los Angeles · R01 · FY2022 · MH
Clinical Development of Novel Therapies for Acute Lymphoblastic Leukemia
$1,329,439Nirali Shah · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
CPS:Medium:Collaborative Research:Information and Computation Hierarchy for Smart Grids
$1,325,000Lang Tong · Cornell University · · FY2011 · CSE
Clinical Genome Resource (ClinGen) Informatics and Production Core
$1,323,964Carlos D. Bustamante · Stanford University · U41 · FY2018 · HG
RTG: Computational Mathematics for Data Science
$1,320,195James G Nagy · Emory University · · FY2021 · MPS
Clonal and imaging analyses of in vivo hematopoiesis, immune cell ontogeny and adoptive cell therapies
$1,318,233Cynthia E Dunbar · National Heart, Lung, And Blood Institute · ZIA · FY2022 · HL
Label-free, single-molecule biosensing at ultrahigh speeds with metasurface-enhanced coherent Raman scattering
$1,316,016Eric Olaf Potma · University Of California-Irvine · R01 · FY2025 · GM
CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy
$1,313,567Arthur P Bertolino · Cytoagents, Inc. · R44 · FY2025 · CA